Literature DB >> 3094208

The influence of the pattern of inflammation and administration of steroids on class II MHC antigen expression in renal transplants.

P Häyry, E von Willebrand.   

Abstract

We have investigated the expression of class II major histocompatibility complex (MHC) antigens in human renal allografts before, during, and after the first episode(s) of rejection, and correlated the antigen expression with the cytological pattern of inflammation as well as with the extent of steroid administration. The results confirm that the class II MHC antigens are rapidly lost from a renal transplant after successful transplantation. Downregulation of graft class II antigenicity was observed in all three immunosuppressive regimens employed, with a steroid dose ranging from 0.5 +/- 0.2 mg/kg/day to 1.8 +/- 0.3 mg/kg/day of methylprednisolone. During rejection the class II MHC antigens reappear in the graft parenchymal (vascular endothelial and tubular) cells, whereas after the successfully treated episode they again disappear from the graft. The upregulation of graft antigenicity is associated only with inflammatory patterns with a distinct blastogenic component; nonblastogenic patterns of inflammation are not associated with upregulation of class II antigens. During blastogenic inflammation, the extent of class II antigen expression was inversely proportional to the amount of steroid administered. The results support the suggestion that upregulation of class II antigen contents in a graft is due to (gamma-interferon released by) the inflammatory (T) blast cells, and suggest that a major downregulating mechanism of class II antigen expression is administration of glucocorticosteroids.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094208     DOI: 10.1097/00007890-198610000-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.

Authors:  Rene J Duquesnoy; Yehia Awadalla; Jon Lomago; Larry Jelinek; Judy Howe; Dwayne Zern; Betty Hunter; Joan Martell; Alin Girnita; Adriana Zeevi
Journal:  Transpl Immunol       Date:  2007-10-30       Impact factor: 1.708

2.  Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group.

Authors:  N R Sinclair
Journal:  CMAJ       Date:  1992-09-01       Impact factor: 8.262

3.  Renal allograft rejection: induction and function of adhesion molecules on cultured epithelial cells.

Authors:  Y Lin; J A Kirby; K Clark; B K Shenton; J L Forsythe; G Proud; R M Taylor
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

4.  The two-edged sword of large-dose steroids for spinal cord trauma.

Authors:  S Galandiuk; G Raque; S Appel; H C Polk
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

5.  Renal allograft rejection: protection of renal epithelium from natural killer cells by cytokine-induced up-regulation of class I major histocompatibility antigens.

Authors:  Y Lin; G Proud; R M Taylor; J A Kirby
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

6.  Induction of HLA-DR expression on thyroid follicular cells by cytomegalovirus infection in vitro. Evidence for a dual mechanism of induction.

Authors:  E L Khoury; L Pereira; F S Greenspan
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

7.  Activation of lymphocytes after platelet allotransfusion possessing only class I MHC product.

Authors:  E Pócsik; R Mihalik; E Gyódi; M Réti; K Pálóczi; G G Petrányi; M Benczúr
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

8.  Repression of major histocompatibility complex IA expression by glucocorticoids: the glucocorticoid receptor inhibits the DNA binding of the X box DNA binding protein.

Authors:  A Celada; S McKercher; R A Maki
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.